Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GILD

3 High-Yield Dividend Stocks to Buy in a Sea of Market Volatility

The latest jobs report indicated that the Fed’s aggressive rate hikes have begun to yield results, but they still have a long way to go. With the market likely to be choppy in the near term, investors could invest in high-yield dividend stocks Gilead Sciences (GILD), KT Corp. (KT), and…

StockNews.com

Want Passive Income in a Bear Market? Check out This Biotech Stock

With the minutes of the latest Fed meeting showing that interest rates will keep increasing this year, the economy is widely expected to enter a recession. Amid the expected downturn this year, it could be wise to buy biotech stock Gilead Sciences (GILD) due to its solid growth prospects and…

StockNews.com

2 Biotech Stocks to Buy Amid a Blazing Hot Run

A rapidly aging population and the rise in lifestyle diseases drive the biotech industry’s growth. Through their cutting-edge research, biotech companies are coming up with new solutions to develop treatments. Given the solid long-term prospects of the industry, it could be wise to buy fundamentally strong biotech stocks Amgen Inc.…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Consider Buying These 2 Biotech Stocks Before 2023

The biotech industry is expected to thrive amid the increasing medical requirements and greater investments in research and development. Moreover, investor sentiment toward biotech stocks has dramatically improved in recent months as the recession possibilities are rising. As this sector is known to provide a hedge against market downturns, investors…

StockNews.com

2 COVID-19 Stocks That Are Still Strong Buys

Given that COVID-19 is here to stay for the foreseeable future, investors could still benefit from their investments in companies that saw record-breaking sales during the pandemic’s height because of the effectiveness of their products in fighting the virus. With the potential resurgence of COVID-19 in several countries, Pfizer (PFE)…

StockNews.com

Up More than 19% In 2022, Is Gilead Sciences Still a Buy?

Gilead Sciences (GILD) beat revenue and earnings estimates in the previous quarter and upgraded its guidance for fiscal 2022. Having risen more than 19% year-to-date, is GILD still a buy? Read on to learn our view.

StockNews.com

3 Biotech Stocks to Help You Build a Healthy Portfolio

Biotech industry played a vital role amid the pandemic and continues to witness solid demand amid rising medical needs and chronic diseases. Investor sentiment toward biotech stocks is robust. As biotech is considered a defensive sector against market downturns, investors might buy quality biotech stocks Gilead Sciences (GILD), Biogen (BIIB),…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

GILD Stock: Is It Still a Smart Investment Ahead of 2023?

GILD gained prominence during the pandemic, but the company’s COVID-19 drug Veklury registered a decline in sales because of declining COVID-19 cases. However, it beat revenue and earnings estimates in the previous quarter. Will the company be able to record further growth in the coming year? Read more to learn…

StockNews.com

3 Stocks to Buy Now for Less Than a Fancy Dinner Out

Although inflation seems to be slowing, the possibility of the Fed continuing rate hikes has led to recessionary concerns. Given the uncertainties ahead, we advise our investors to invest in fundamentally sound stocks, Coca-Cola (KO), Gilead Sciences (GILD), and PBF Energy (PBF). These stocks are currently trading at a relatively…

StockNews.com

The 3 Best Dividend Stocks to Purchase Right Now

Rising market uncertainties and recessionary fears, anticipated to hit in 2023, have led investors to safeguard their portfolios and ensure a steady flow of income. Against this backdrop, quality dividend stocks Natural Resource Partners (NRP), Spok Holdings (SPOK), and Gilead Sciences (GILD) could be best purchases now. Read on….

StockNews.com

3 Biotech Stocks to Buy Before December and 1 to Sell

The biotech industry is increasingly gaining prominence due to the growing prevalence of chronic disease and advancements in drug discovery and development. Given the industry’s solid growth prospects, it could be wise to buy quality biotech stocks, Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and United Therapeutics (UTHR). However, we think…

StockNews.com

2 Biotech Stocks to Add to Your Portfolio in Q4

Despite lingering macro issues, the biotech industry is expected to witness robust growth. Moreover, amid rising medical needs and chronic diseases, research and development in the biotech sector are expected to expand, contributing to its growth. Therefore, investors might add quality biotech stocks Gilead Sciences (GILD) and Biogen (BIIB) to…

StockNews.com

2 Biotech Stocks to Buy in November and 1 to Sell

The biotech industry strengthened over the pandemic by drug and vaccine development initiatives to combat COVID-19. Moreover, significant government investments should bode well for this industry. Therefore, quality biotech stocks Amgen (AMGN) and Gilead Sciences (GILD) could be ideal buys in November. However, fundamentally weak stock Ginkgo Bioworks (DNA) might…

StockNews.com

2 Dividend Stocks You Shouldn’t Wait Any Longer to Buy

Amid rising market uncertainties, investors are increasingly opting for dividend stocks to safeguard their portfolios and ensure a steady income stream. We believe fundamentally sound stocks Gilead Sciences (GILD) and Flowers Foods (FLO), which have impressive dividend-paying records, are ideal additions to your portfolio now. Keep reading….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

The 4 Best Stocks to Buy This November

Favorable inflation data for October has raised the odds of slower federal rate hikes ahead. The market has been celebrating the inflation report, and experts believe the current rally could sustain for a while. Therefore, investors could buy quality stocks such as Gilead Sciences (GILD), Biogen (BIIB), Hillenbrand (HI), and…

StockNews.com

Is Gilead Sciences Still a Buy Post COVID-19?

Gilead Sciences’ (GILD) popular covid product Veklury (Remdisivir) witnessed declining sales in the post-pandemic era. However, the company’s top line, excluding Veklury, has seen steady growth. Moreover, despite ongoing market volatility, the stock has registered stable gains. So, let’s find out if GILD is still a buy in the post-covid…

StockNews.com

2 Stocks Investors Should Load up on Before 2022 Ends

The stock market is experiencing high volatility amid the Fed’s campaign against inflation and rising recession odds. However, chances remain that the Fed might pull off a soft landing. We think it could be the right time to buy fundamentally solid stocks AT&T (T) and Gilead Sciences (GILD). Read on….

Benzinga

Gilead Sciences Unusual Options Activity

Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

1 Stock to Buy This Week Following Its Recent Earnings Beat

Biopharmaceutical giant Gilead Sciences (GILD) reported better-than-expected third-quarter earnings and sales and raised its full-year guidance. Analysts see immense growth potential in the company’s HIV and oncology franchises, which should boost its performance in the upcoming quarters. Given its strong earnings, high profitability, discounted valuation, and attractive dividend, we think…

Benzinga

Check Out What Whales Are Doing With GILD

StockNews.com

2 No-Brainer Biotech Stocks to Buy Right Now and 1 to Sell

The biotech industry is set to benefit from continued investments in breakthrough developments and federal support. Against this backdrop, fundamentally strong biotech stocks Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) could be solid buys. However, Relmada Therapeutics (RLMD) might be best avoided considering its weak fundamentals. Read on….

Benzinga

Gilead Sciences Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

StockNews.com

3 Biotech Stocks to Buy for Q4 and 1 to Avoid

Favorable federal investments are anticipated to fuel further expansion in the biotech industry. Given the sector’s good prospects, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys. However, fundamentally weak stock Intra-Cellular Therapies (ITCI) might be best avoided. Read on….

Benzinga

What Are Whales Doing With Gilead Sciences

A whale with a lot of money to spend has taken a noticeably bullish stance on Gilead Sciences. Looking at options history for Gilead Sciences (NASDAQ:GILD) we detected 17 strange trades.

StockNews.com

3 Biotech Stocks That'll Make You Richer and 1 That Won't

The biotech industry continues to stay resilient to broader economic challenges. Moreover, the planned multi-million-dollar government investments should bode well for the industry. Hence, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys to cash in on the industry’s prospects. However, fundamentally weak stock…

1 … 5 6 7 8

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

Sristi Suman Jayaswal

90 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.